Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 21, 2014; 20(31): 10740-10751
Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.10740
Table 2 Largest studies in borderline resectable pancreatic cancer
AuthorYearStudy typeStudy sizeNumber with borderline resectable (definition)NeoadjuvantResectedNegative marginsMedian OS (mo)
Chuong et al[86]2013Single institution retrospective7357 (NCCN)Majority gemcitabine based induction chemotherapy, SBRT56%96%16.4
Katz et al[87]2012Single institution retrospective129115 (AHPBA/SSAT/SSO/NCCN)Gemcitabine based chemotherapy and chemoradiation or chemoradiation alone84% or 78%95%1331
or
72 (MDA)
Barugola et al[91]2012Single institution retrospective36227 (other)Gemcitabine based chemotherapy and chemoradiation or chemotherapy aloneNRNRNR
Kang et al[93]2012Single institution retrospective20235 (NCCN)Gemcitabine based chemoradiation91%87%26.3
Stokes et al[81]2011Single institution retrospective17040 (MDA)Capecitabine-based46%75%23
Chemoradiation
Chun et al[78]2010Single institution retrospective109109 (other)5-FU or gemcitabine based chemoradiation100%59%2232
74 received neoadjuvant2
McClaine et al[103]2010Single institution retrospective2929 (MDA+NCCN hybrid)Gemcitabine based chemotherapy, chemoradiation or both46%67%23.3
Landry et al[84]2010Randomized Phase II trial2121 (other)Gemcitabine based24%60%26.3
Turrini et al[89]2009Single institution retrospective6449 (MDA)5-FU/cisplatin based chemoradiation18%100%24
Katz et al[31]2008Single institution retrospective160160 (MDA)Gemcitabine based chemotherapy, chemoradiation41%94%40